Basal Cell Carcinoma Histology Explained

Basal cell carcinoma (BCC) has a distinctive appearance under the microscope that sets it apart from most other skin cancers. Pathologists look for clusters of small, dark-staining cells with a characteristic arrangement at their edges, surrounded by a stroma that often pulls away from the tumor nests during tissue processing. These features, along with the specific growth pattern the tumor adopts, determine its subtype and directly influence treatment decisions. Understanding what a pathology report describes can make the difference between a straightforward office procedure and a more involved surgical plan.

The Signature Features Pathologists Look For

When a pathologist examines a BCC biopsy, the first things they check for are three hallmarks that, taken together, strongly point toward the diagnosis. The most reliable is peripheral palisading, where the outermost row of tumor cells lines up in a neat fence-like arrangement at the edge of each tumor nest. Second is retraction artifact, a gap that forms between the tumor nests and the surrounding connective tissue during tissue processing. Third is increased mucin in the stroma surrounding the tumor. All three features together are considered extremely suggestive of BCC and rarely appear in combination in other tumor types.¹

That said, none of these features is perfectly unique to BCC. Peripheral palisading can show up in certain benign tumors, and it can be inconspicuous or absent in some BCCs, particularly the more aggressive growth patterns. This is why pathologists weigh the whole picture rather than relying on any single clue.

Where BCC Cells Actually Come From

The name “basal cell” suggests these tumors arise from the flat basal layer of the skin’s surface, and for decades that was the working assumption. Research in mice has complicated that picture considerably. Multiple studies using genetic tools to activate tumor-driving mutations in different compartments of the skin have shown that hair follicle stem cells are a particularly efficient source of BCC-like tumors, while stem cells in the flat skin between follicles are much less efficient at generating them.² One study found that innervated progenitor cells in mechanosensory touch domes, the structures around certain hair follicles that help detect touch, are highly tumorigenic.

The cell of origin also appears to influence what the tumor looks like under the microscope. When researchers activated the Hedgehog signaling pathway specifically in resting hair follicle stem cells, the mice developed tumors resembling nodular BCC. When the same pathway was activated in the flat epidermis between follicles, the result looked more like superficial BCC.³ The level of oncogenic signaling mattered too, with high-level signaling needed to drive tumors from the interfollicular epidermis. This means the histological subtype you see on a pathology report may partly reflect which cell population was hijacked in the first place.

Nodular BCC Under the Microscope

Nodular BCC is the most common subtype, and it is the one most people picture when they think of this cancer. Under the microscope, it consists of well-defined large or small nests of basaloid cells sitting in the dermis. The hallmark slit-like retraction between tumor nests and surrounding stroma is usually prominent. Roughly a third of nodular BCCs also have a superficial component running along the surface.⁴

The stroma around nodular tumors tends to show a mucin-rich, myxoid quality rather than dense scarring. Cell division and individual cell death within the nests are uncommon, which is one reason nodular BCC generally behaves in an indolent way. An interesting processing artifact can happen with this subtype: the retraction gaps can become so pronounced that tumor nests fall out entirely during slide preparation, leaving behind empty rounded spaces in the dermis. Pathologists trained to recognize these “ghost nests” can still make the diagnosis even though the tumor cells themselves have dropped away.⁴

Superficial BCC

Superficial BCC looks quite different from nodular. Instead of round nests pushing deep into the dermis, it consists of buds and lobules of basaloid cells hanging down from the undersurface of the epidermis, staying in the upper dermis. These tend to be multifocal, meaning several separate tumor buds can be scattered along a stretch of skin, which is why superficial BCCs sometimes recur after treatments that target only the visible center of the lesion. Population data from the Netherlands found that superficial BCC occurred at a younger age than nodular, particularly in women.⁵ Age-standardized incidence rates for nodular BCC were roughly double those of superficial BCC in both sexes, confirming nodular as the dominant subtype.

When the Growth Pattern Turns Aggressive

Some BCC subtypes grow in ways that make them harder to detect clinically and harder to remove completely. These are grouped under “aggressive” or “high-risk” growth patterns, and recognizing them on histology is critical because it changes the recommended treatment approach.

Infiltrative BCC

Infiltrative BCC sends irregular strands and spiky clusters of tumor cells into the dermis, often without well-defined borders. There is little or no retraction artifact, meaning the tumor blends more seamlessly into surrounding tissue. The stroma tends to be dense and fibrotic rather than the loose, mucin-rich type seen in nodular tumors. These features make the tumor edges difficult to define during surgery.

Morpheaform (Sclerosing) BCC

Morpheaform BCC, named because it clinically resembles a patch of scar-like skin called morphea, consists of thin strands and cords of tumor cells embedded in a dense, collagen-rich stroma. The tumor can extend well beyond its visible borders. A study of morpheaform BCCs found that the majority demonstrated areas where individual tumor cells separated from the main nests and infiltrated the stroma as single cells, sometimes spreading nearly a millimeter from the main tumor mass.⁶ That single-cell infiltration pattern makes it especially challenging to achieve clear surgical margins.

Micronodular BCC

Micronodular BCC resembles nodular BCC at first glance, but the tumor nests are much smaller. This is deceptive because the small nests spread more widely and deeply than the clinically apparent lesion suggests. A study comparing micronodular and nodular BCCs treated with Mohs surgery found that micronodular tumors required significantly more surgical stages, wider tissue removal, and left deeper defects.⁷ Its depth of invasion is comparable to infiltrative BCC and substantially deeper than nodular BCC. No nodular BCCs in one comparative study invaded to Clark level IV, while roughly a tenth of micronodular BCCs did.⁸

Uncommon Variants Worth Knowing

Fibroepithelioma of Pinkus

Fibroepithelioma of Pinkus (FeP) is a rare and unusual variant that looks nothing like a typical BCC either clinically or under the microscope. Instead of nests of basaloid cells, it consists of thin, interconnecting strands of basaloid or squamous-looking cells that project downward from the epidermis in a web-like, fenestrated pattern. These strands sit within an abundant fibrous stroma, and at the edges of the fenestrations you can sometimes see small bud-like structures resembling hair follicle germs.⁹ FeP typically presents as a flesh-colored, dome-shaped nodule on the lower back, a location unusual for most BCCs. Despite its odd appearance, it is classified as a BCC variant and behaves in a generally indolent manner.

Basosquamous Carcinoma

Basosquamous carcinoma (BSC) sits at the boundary between BCC and squamous cell carcinoma and is considered more aggressive than either of its parent types. Under the microscope, BSC shows areas of typical basaloid cells alongside nests of squamous cells, connected by a transition zone where the cells shift from one morphology to the other.¹⁰ BSC has a higher tendency toward local recurrence and, unlike ordinary BCC, a real propensity for lymph node and distant metastases.¹¹ Identifying the transition zone is the key diagnostic step, and special staining with BerEP4, which marks basal cells, can help. In BSC, BerEP4 staining shows a gradient: strong in the basaloid areas, fading through the transition zone, and absent in the squamous regions.¹⁰

Immunohistochemistry and the Staining Panel

Sometimes the microscopic appearance alone is not enough to confirm a diagnosis. This is where immunohistochemistry (IHC) comes in, using antibodies that bind to specific proteins to light up certain cell types. Two markers in particular are workhorses for BCC diagnosis.

BerEP4 is an antibody that reliably stains BCCs of all types and can distinguish BCC from squamous cell carcinoma, where it is negative. However, BerEP4 also stains some benign hair follicle tumors like trichoepithelioma and trichoblastoma, so it cannot tell those apart from BCC on its own.¹² CD10 fills that gap. In BCC, CD10 stains the tumor cells themselves, while in trichoblastoma and trichoepithelioma the staining highlights the stroma around the tumor rather than the cells within it. Squamous cell carcinoma tumor cells are almost always negative for CD10. Using BerEP4 and CD10 together creates a reliable panel for separating BCC from its most common look-alikes.¹²

Another marker, PHLDA1, has shown promise specifically for the tricky distinction between morpheaform BCC and desmoplastic trichoepithelioma, two tumors that can look nearly identical on routine staining. Morpheaform BCCs almost always lack PHLDA1 staining, while about three-quarters of classical and nearly nine in ten desmoplastic trichoepitheliomas stain strongly.¹³ There is a catch with micronodular BCC: roughly a third of those cases showed focal to diffuse PHLDA1 staining, so the marker is less cleanly negative in that subtype.

Tricky Look-Alikes and Diagnostic Pitfalls

One of the most common diagnostic challenges is telling BCC apart from benign tumors that arise from hair follicle structures, particularly trichoepithelioma and trichoblastoma. On a small punch biopsy, some of the most helpful distinguishing features for trichoepithelioma, like symmetry, good circumscription, and a central depression, simply cannot be evaluated because the specimen is too small to see the overall architecture.¹⁴ In those situations, pathologists rely on secondary clues: signs of follicular or sebaceous differentiation, calcification, or the absence of sun damage beneath the lesion all favor trichoepithelioma over BCC.

During Mohs surgery, where tissue is examined as frozen sections cut in a horizontal plane, the list of potential mimics grows. Hair follicles cut in cross-section can look alarmingly similar to small BCC nests. Folliculocentric basaloid proliferations, poromas, sebaceous glands affected by nevus sebaceus, and even spiradenomas can all cause confusion when viewed in an unfamiliar plane of section.¹⁵ Frozen sections also introduce their own artifacts, including ice crystal damage and compression, that can obscure the very features pathologists depend on for diagnosis.

Perineural Invasion as a Red Flag

When a pathologist reports perineural invasion, meaning tumor cells have grown along or around a nerve, it is one of the most significant histological findings in a BCC. Perineural invasion is uncommon in BCC overall, but when present it signals a substantially higher risk of recurrence. A systematic review pooling data from 159 patients with BCC showing perineural invasion found that about a third experienced at least one recurrence.¹⁶ The median follow-up for patients who did not recur was roughly 31 months, compared with 21 months for those who did, which suggests that some of the “non-recurrence” group may simply not have been followed long enough. Perineural invasion often prompts more aggressive treatment, including wider excision margins and sometimes adjuvant radiation.

How Treatment Changes What Pathologists See

Targeted therapy with vismodegib, a Hedgehog pathway inhibitor used for advanced BCC, can dramatically alter the tumor’s appearance under the microscope. In a series of 19 patients treated with vismodegib, about a third achieved a complete response where tumor was replaced entirely by a hyaline scar with inflammatory cells and small cysts. Among those with partial responses, roughly half showed the tumor shifting its appearance toward a more squamous or metatypical look.¹⁷

These treatment-induced changes are not just academic curiosities. The shift toward squamous differentiation can cause BerEP4 staining to become negative, which creates a real diagnostic problem for pathologists trying to confirm whether residual tumor is present.¹⁸ Other histological changes seen during and after treatment include extensive tumor necrosis with pyknotic nuclei, fibrosis and scarring, and an increase in plasma cells within the surrounding tissue.¹⁹ Pathologists who are not told that a patient has been on vismodegib could potentially misinterpret these findings.

The Immune Landscape Under the Microscope

Beyond the tumor cells themselves, pathologists increasingly pay attention to the immune cells surrounding BCC. The density and composition of tumor-infiltrating lymphocytes (the immune cells that have entered the tumor) vary across subtypes and carry implications for newer immunotherapy approaches.

In a study of aggressive BCCs, all 34 tumors examined showed expression of both PD-1 and LAG-3 on their infiltrating immune cells. The correlation between PD-1 and LAG-3 density was strong, and LAG-3 was expressed at roughly half the level of PD-1.²⁰ This co-expression pattern matters because it suggests the tumor’s immune evasion involves multiple checkpoint pathways simultaneously. In a case report from the same study, a patient with locally advanced BCC who had stable disease on anti-PD-1 therapy alone showed a partial response after anti-LAG-3 was added. Biopsies taken throughout treatment showed LAG-3 levels climbing after anti-PD-1 treatment started, suggesting the tumor was compensating by upregulating an alternative escape route.

The relationship between immune checkpoint markers and immune cell density is not straightforward across all subtypes. One analysis found that basosquamous BCC showed positive PD-L1 expression in every case, while nodular and infiltrative subtypes were more variable. Overall TIL infiltration was moderate in the majority of tumors, but no significant correlation between PD-L1 expression and TIL density was found.²¹ This disconnect between checkpoint marker expression and actual immune cell numbers is one reason predicting immunotherapy response from a biopsy remains difficult.

Mohs Surgery and Frozen Section Challenges

Mohs micrographic surgery relies on examining the entire surgical margin in horizontal frozen sections, which is what gives it its famously low recurrence rates. The surgeon removes a thin layer of tissue, maps it, and a technician freezes it, cuts it, and stains it so the surgeon can check whether any tumor remains at the edge. If tumor is present, only the involved area is re-excised. This iterative process continues until all margins are clear.²²

The catch is that frozen sections are lower quality than the permanent sections prepared in a standard pathology lab. Ice crystal formation, compression artifacts, and the horizontal orientation (which is different from the vertical slices pathologists normally read) all create room for error. Normal structures cut at unusual angles can mimic tumor nests. Research into nonlinear microscopy techniques has shown promise in reproducing the diagnostic features seen on frozen sections without the need for cryosectioning, which could eventually speed up the process while maintaining accuracy.²² For now, the speed and quality of frozen section interpretation remains one of the rate-limiting steps in Mohs surgery, and recognizing the artifacts it introduces is a skill that takes years of practice.

Optical Coherence Tomography as a Non-Invasive Window

While traditional histology requires cutting out tissue, newer imaging methods are beginning to offer a look at BCC structure without a scalpel. Optical coherence tomography (OCT), which uses light waves to create cross-sectional images of tissue in real time, has been studied as a tool for characterizing BCC before biopsy. In a study of periocular BCCs, OCT images reliably identified dark (hyporeflective) nodules with bright edges in all 15 tumors examined, corresponding to the basaloid tumor nests and peripheral palisading seen on traditional slides. Epidermal thinning was present in every case, and dark borders around the tumor, corresponding to the retraction cleft seen on histology, appeared in about three-quarters of cases.²³ OCT cannot replace a biopsy for definitive diagnosis or subtyping, but it may help guide where to biopsy and how to plan surgical margins, particularly in cosmetically sensitive areas around the eyes.

1
Current Diagnostic Pathology. Basaloid skin tumours: Basal cell carcinoma
2
PubMed Central. Basal cell carcinoma preferentially arises from stem cells within hair follicle and mechanosensory niches
3
PubMed Central. Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations
4
Modern Pathology. Histopathology of basal cell carcinoma
5
Oxford Academic (British Journal of Dermatology). Basal cell carcinoma: histological classification and body-site distribution
6
PubMed. Morpheaform Basal Cell Carcinomas With Areas of Predominantly Single-Cell Pattern of Infiltration: Diagnostic Utility of p63 and Cytokeratin
7
PubMed. Micronodular basal cell carcinoma. A deceptive histologic subtype with frequent clinically undetected tumor extension
8
PubMed. Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas
9
PubMed Central. Fibroepithelioma of Pinkus Revisited
10
PubMed. Reappraising basosquamous carcinoma: a summary of histologic features, diagnosis, and treatment
11
PubMed Central. Basosquamous carcinoma: histopathological features
12
PubMed Central. Expression of BerEP4 and CD10 IHC Markers in Basal Cell Carcinoma, Squamous Cell Carcinoma and Adnexal Tumours of Follicular Differentiation: A Comparative Study
13
PubMed. Differential expression of PHLDA1 (TDAG51) in basal cell carcinoma and trichoepithelioma
14
PubMed. Desmoplastic trichoepithelioma versus morphoeic basal cell carcinoma: a critical reappraisal of histomorphological and immunohistochemical criteria for differentiation
15
PubMed. Histopathologic pitfalls of Mohs micrographic surgery and a review of tumor histology
16
PubMed. Basal Cell Carcinoma With Perineural Invasion: A Systematic Review and Pooled Survival Analysis
17
PubMed. Histologic Changes During Treatment With Vismodegib in Locally Advanced Basal Cell Carcinoma: A Series of 19 Cases
18
PubMed Central. Histologic changes of basal cell carcinomas during vismodegib treatment
19
Journal of Drugs in Dermatology. Histopathology of Basal Cell Carcinoma After Treatment With Vismogedib
20
PubMed Central. Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade
21
Bioscientia Medicina : Journal of Biomedicine and Translational Research. Beyond Co-Expression: Unraveling the Complex Relationship Between PD-L1 and Tumor-Infiltrating Lymphocytes in Basal Cell Carcinoma Subtypes
22
PubMed Central. Comparison of nonlinear microscopy and frozen section histology for imaging of Mohs surgical margins
23
PubMed Central. A novel imaging approach to periocular basal cell carcinoma: in vivo optical coherence tomography and histological correlates